Cytoskeleton and extracellular matrix-related proteins (CECMPs) represent the most common class of cancer mutants, owing to the large size of their coding regions and the randomness of mutagenesis. We used a bioinformatics approach to assess the impact of amino acid (AA) substitutions on the sensitivity of CECMPs to proteases relevant to melanoma and on the binding affinities for HLA class I. CECMP peptides with AA substitutions overwhelmingly reflect increased sensitivity to proteases implicated in melanoma development (MME, CTSS, MMP2, CTSD, CTSL) in comparison to the wild-type peptide sequences. Furthermore, peptides with AA substitutions representing increased peptide protease sensitivity also represented relatively high binding affinities for HLA class I allelic variants. These analyses raise the question of whether increased protease sensitivity, of mutant cancer peptides represents a significant increase in the availability of cancer mutant, HLA class I epitopes and a hitherto unappreciated aspect of cancer cell immunogenicity, particularly in the case of melanoma?
Major aspects of cancer development and progression remain unresolved and unclarified, for example, metastasis and ineffective, anticancer immune responses in normal persons, that is, persons not receiving immunosuppressive drugs or immunocompromised in other ways. In the case of metastasis, there has been considerable emphasis on metastasis suppressor proteins or signaling pathways that have the potential of distinguishing metastatic variants from primary cancers. However, these approaches have not yielded any clear opportunities to distinguish metastatic cells from primary tumor cells. For example, classical tumor suppressor genes differ from proposed metastasis suppressor genes in gene sizes, thus offering a possible explanation for the earlier mutations of classical tumor suppressor genes, in the course of tumor development-bigger genes are bigger mutagen targets-that would not be related to a nonmetastatic function. 1 And, metastasis suppressor proteins have yet to yield clear biochemical distinctions from classical tumor suppressor genes.
For example, many metastasis suppressor genes participate in the same biochemical regulatory processes as do the classical tumor suppressor genes. 1 Thus, new models of metastasis need to be considered.
One possibility is that primary tumor spread is limited by the restraint on physical barriers to tumor cell escape from an initial location, 2 as suggested by concerns regarding morcellation 3, 4 and the long-term appreciation of basement membrane degradation in cancer staging. [5] [6] [7] Cancer cell derived enzymatic activity has been implicated in ECM degradation. [8] [9] [10] Considering the possibility of physical barriers, or the degradation of physical barriers in relation to metastasis further suggests considering the possibility that abnormal, [11] [12] [13] [14] or abnormally expressed 15, 16 cell shape and ECM proteins could facilitate metastasis. [17] [18] [19] As it turns out, proteins that participate in the formation of the cytoskeleton and extracellular matrix (CECMPs) represent very large coding regions and thereby are frequently mutated in tumorigenesis, 20, 21 that is, the random nature of mutagenesis makes it inevitable that many of these coding regions will be mutated. In some cases, particularly in melanoma, these coding regions have been shown to be candidate drivers. 22 Furthermore, the vast occurrence of CECMPs with mutant AA makes the CECMP mutant collection relevant in the consideration of neo-antigen-based processes. That is, several studies have indicated that therapies designed to stimulate the immune system, in particular immune checkpoint based therapies, are more successful when tumors have high mutation loads. [23] [24] [25] [26] [27] And, it is clear that CECMP peptides are very common epitopes for HLA class I and class II antigen-presenting molecules. 21, 28 Thus, we evaluated the impact of AA substitutions in a CECMP set previously indicated to be commonly mutated in a series of cancer datasets, 20 with regard to alterations in protease sensitivity; and in HLA class I binding affinities, in both cases using bioinformatics tools. The results show a striking increase in the protease sensitivity of CECMP mutant peptides and a strong correlation between HLA class I high binding, candidate epitopes and mutant peptides with increased protease sensitivity. These results point to novel directions for explanations of metastasis, and raise the question of whether lack of antitumor immunity can be traced to high-level protease sensitivity of some of the better neo-antigen/ HLA class I binders.
Methods
Identification and collection of mutant cytoskeletonrelated peptides from the TCGA database
Mutant amino acid (AA) substitutions in cytoskeleton-related proteins previously reported as frequently mutant, and as candidate driver proteins in TCGA datasets 20, 22 in cancer (Table   1) were collected from www.cBioPortal.org. Truncating mutations were excluded, and mutations within 8 codons of the ends of the coding regions. The latter exclusion was due to the limitations of the protease digestion algorithms. The list of AA substitutions used in this report from all the datasets used are available in the Supporting Information, Table S1 .
Assessment of protease sensitivity of mutant peptides
Protease cleavage matrices were obtained from MEROPS 29, 30 Sanger Database (merops.sanger.ac.uk/cgi-bin/namesearch.pl) for proteases where there have been significant reports in the literature that the proteases are associated with melanoma development. These matrices are available in the Supporting Information, Table S2 . The proteases have the following HUGO symbols, with melanoma relevance citations: MME (neprilysin), CTSS(cathepsin S), MMP2 (matrix metalloproteinase-2), CTSD (cathepsin D), CTSL (cathepsin L). 31 The protease matrices were stored in a comma separate value (CSV) file format which was used as an input file for the USF-ProteaseMutantDigestion-BC.pl (Supporting Information, Table S3 ), an original program for high-output processing of the MEROPs algorithms. Specifically, these matrices were used to create a scoring system for determining alterations in protease sensitivity due to the AA substitutions in mutant peptides from the cytoskeletal and ECM protein set (Table 1) , in comparison to the analogous, wild-type peptide. Using the position of the mutant AA substitution, both a wild-type peptide sequence and a mutant peptide sequence were generated from a list of known wild-type peptide sequences obtained from the human proteome at uniprot.org. The wild-type AA sequences for the Table 1 proteins used in this report are in the Supporting Information, Table S4 . The mutant peptide and the analogous wild-type peptide were scored individually, and the difference of the scores was used to quantify the increase or decrease of the sensitivity attributable to the mutant AA substitution. A threshold of 90% of a protease's maximal cleavage score was required for further consideration and processing in this report, to work with only significant mutations. In other words, unless there was a 90% drop in sensitivity, or a 90% increase in sensitivity, based on the largest difference in scores for individual AA throughout the entire protease matrix, the AA substitution was no longer considered for further analysis and was not included in any aspects of the Results section. For example, if across 8 AA positions of the protease matrix, and down the column of 20 AA, representing 160 values in the matrix, as provided by the MEROPS Sanger Database, there was at least one "0" and one value of "1000," a mutant AA substitution would have needed to increase or decrease a value by 900. Thus, if AA X replaced an AA Y representing "0" in the wild-type peptide, such that AA X had a value of 900, according to the MEROPS matrix, this alteration would have been included in subsequent steps, because 900 represents 90% of greatest difference in the matrix. Or, if AA X replaced AA Y representing a value of "1000," and AA X had a value of 100, then AA X would have been included. The mutant peptides were evaluated for each possible mutant AA position within the matrices. Scores for each position were produced and the greatest absolute score was taken for each mutant AA to determine whether the 90% threshold was met. A worked example of the scoring process is available in the Supporting Information, Table S5 . As noted in more detail in Results, the above protocol for assessing the impact of AA substitutions in the Table 1 coding region set was also undertaken for the colon (COAD) and bladder (BLCA) TCGA cancer datasets. The resulting analyses for these datasets are exclusively in the Supporting Information, Table S6 . in addition to the proteases associated with the above cancers, two control proteases were
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selected on the basis of their lack of association with the corresponding cancers, granzyme B and caspase 1.
31
RNASeq results obtained from cBioPortal.org
RNASeq data were retrieved from cBioPortal.org for protease gene expression levels, as noted in Results. The entire RNASeq dataset used in this report is in the Supporting Information, Table S7 . RNASeq raw counts were used to make a determination of whether the SKCM dataset could be subdivided into samples representing statistically significant, distinct high and low expressing sets, for the indicated protease genes.
Global HLA class I epitope binding analysis
Using the AA substitutions identified as indicated above, peptide sequences were generated and analyzed with regard to whether the AA substitution would impact HLA class I binding. A standard set of alleles that covers a large spectrum of the population was used. 32 Determination of HLA class I alleles for the TCGA SKCM dataset and assessment of HLA class I/cytoskeleton-and ECM-related, mutant peptide binding affinities HLA-A, HLA-B and HLA-C alleles were determined using Optitype 33 installed at USF research computing from a 
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Spectrin repeat containing, nuclear envelope 2 Figure 1 . Overview of the processing steps used to evaluate potential alterations in protease sensitivity due to mutant amino acids (AA) in the CECMP set. The MEROPs, Sanger protease database consists of protease matrices, which have been constructed from in vitro experimental data. The scores at each AA position along any given protease matrix correspond to the number of times a particular amino acid has been found experimentally at that position, while a protease cleaved the peptide bond between positions P1 and P1 0 . These protease matrices are the basis for the scoring system for this report. The system (processing steps in this figure) scores wild-type AA sequences and mutated AA sequences separately. The difference between wild-type score and mutant score is then used as a measure of whether a given CECMP AA substitution makes a peptide more or less sensitive to protease digestion.
source at github.com (The pipeline for use of Optitype on USF research computing is available in the Supporting Information, Table S8 . The Optitype software has an accuracy of 99% (academic.oup.com/bib/article-lookup/doi/10.1093/bib/ bbw097) using RNASeq whole-exome reads. The RNASeq sequencing files for TCGA SKCM dataset were downloaded from the GDC-client portal (gdc-portal.nci.nih.gov) using approval for project #6300. The allele determinations for all TCGA SKCM samples are available in the Supporting Information, Table S9 . The HLA class I alleles for 10 tumor samples were verified using WXS blood-derived samples downloaded from GDC-client portal, thus verifying the accuracy of the software and the accurate use of the software. See verification of individual HLA class I typing results in the Supporting Information, Table S10 .
Patient MHCI allele and patient peptide MHCI binding analysis. Using the HLA-A and HLA-B alleles determined from the protocol above and using the same epitopes generated as in the global epitope analysis, patient alleles were matched to their corresponding mutant peptide sequences. Once again, tallies of the number of high and intermediate binding epitopes were obtained for peptides with increased protease sensitivity and resistance, respectively, resulting from the above indicated analysis of the impact of AA substitutions in Table 1 coding region set, as detailed in Results.
Outcome analysis. To evaluate whether patients with CECMP AA substitutions with increased protease sensitivity experienced a difference in survival from melanoma patients that did not possess such mutations, AA substitutions were matched to their patient barcodes. The barcodes were used to generate Overall survival and disease-free survival KaplanMeier curves at cBioPorta.org. In addition to Kaplan-Meier curves, median survival times were also calculated.
Results

Increased protease sensitivity of CECMPs in melanoma
Previous work has identified a set of commonly mutated CECMPs in numerous cancer datasets, most likely because of the large size of the coding regions for these proteins and the randomness of cancer mutagenesis. 20, 21, 34 For some cancer types, including melanoma, there is evidence that a set of CECMPs represents cancer driver mutations. 22 Thus, we evaluated the mutant peptides representing this CECMP set (Table 1) for protease sensitivity, due to high protease levels in cancer; and for HLA class I binding affinity, because of the importance of immune activation in cancer progression and the potential of proteases interfering with availability of epitopes. 28, 35 The process used for assessing the changes in protease sensitivity or resistance is detailed in Methods and is shown in overview in Figure 1 . All mutant amino acids in the CECMP set, represented by all barcodes (patient samples), in the TCGA-SKCM dataset, available through cBioPortal.org, were collected as input, at the start of the processing steps, as 
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indicated in the flowchart (Fig. 1 ). This process was repeated the TCGA-COAD and TCGA-BLCA datasets, also available from cBioPortal.org. Proteases were selected for this study based on the relevance of the proteases to melanoma, as indicated by ref. 31 (Methods; Table 2 and Fig. 2 ). The study included three tumor types, melanoma (SKCM); and two additional cancer datasets, colon (COAD) and bladder (BLCA), representing relatively few alterations in protease sensitivity, for proteases relevant to those cancer types. The COAD and BLCA results are not discussed further in Results but are available in the Supporting Information, Table S6 . (COAD and BLCA are referred to in Discussion).
To determine whether mutant AA modified the sensitivity of CECMP proteins to the set of proteases under study, we employed the MEROPs algorithms 29, 30 and original software, termed USFProteaseMutantDigestion-BC (Supporting Information, Table S3 ), to process the melanoma mutation databases (Methods). Results indicated a much greater number of CEMCP mutant peptides with increased sensitivity for the melanoma associated proteases, in comparison to mutant peptides where the protease resistance was increased ( Fig. 1 and Table 2 ). The assessment of the CECMP's by the in silico digestion of the control proteases, Granzyme and Caspase 1, which do not have a link to melanoma, 31 showed lower levels of CECMP mutations leading to increased protease sensitivity and a higher number of mutations leading to increased resistance (Fig. 2) . Results also showed that, for the melanoma relevant proteases, there are about 120 TCGA barcodes (out of a total of 479) that contain at least one mutant AA in the CECMP set that leads to increased sensitivity, in the case of each protease (Table 2) . Note these data also represent overlap of multiple proteases. However, there is no quantification presented regarding the number of barcodes that have mutant AA that lead to increased sensitivity for more than one protease. Furthermore, for any given protease, and for any single barcode, there existed a likelihood of that barcode having multiple mutant AA for that protease, whereby the additional mutant AA also lead to increased sensitivity of a member of the CECMP set to cleavage (Table 2) .
To be clear about the above approach, the results for the mutant AA for the CECMP set for one barcode, TCGA-FS-A1ZF, included in Table 2 summary, obtained from cBioPortal.org and used as input for the program, USF-ProteaseMutantDigestion-BC (Methods), are listed in Table 3 . TCGA-FS-A1ZF had only one peptide with an alteration in the cathepsin S sensitivity that met the 90% threshold standard (detailed in Methods), for a change in MEROPs score. This result is indicated in Table 4 . TCGA-FS-A1ZF had a mutant AA substitution that rendered the indicated peptide more resistant to cathepsin S digestion, in comparison to the analogous wild-type peptide (Table 4) .
Subdividing samples based on the cathepsin S expression levels
Cathepsin S was the only melanoma-associated protease for which the barcodes that represented CECMP AA substitutions with increased protease sensitivity also had statistically HUGO symbols for the proteases from left to right are CTSD, CTSL, CTSS, MMP2, MME, GZMB, and CASP1. The melanoma datasets used from cBioPortal.org have Refs. 39-41 and TCGA SKCM set (https://cancergenome.nih.gov/). Note this figure represents the only data analysis that uses melanoma datasets in addition to the TCGA-SKCM dataset, per the preceding references. Note, in Table 2 , this barcode is included among the barcodes having only one, cathepsin S-resistant AA substitution and no sensitive substitutions. As noted below (Table 4) only one of these substitutions-L782H (bold)-meets the 90% threshold for alteration in protease sensitivity from wild-type. The other mutant AA in this list was therefore not further studied in this report. significant higher protease RNA expression levels (Fig. 3) . In other words, stratification of samples based on statistically significant different levels of cathepsin S RNASeq values effectively identified the barcodes with a statistically significant difference in the number of AA substitutions that lead to increased cathepsin S sensitivity, again, keeping in mind the minimum standard applied for the sensitivity difference (90% increase or decrease; Methods) between the relevant peptide with the mutant AA and the same peptide but with the wild-type AA.
Global HLA class I alleles and patient peptide HLA class I binding
We were interested in the question of whether HLA class I binding affinities of the mutant peptides, that had increased sensitivity to the proteases studied above, were different from the binding affinities of the mutant peptides that represented increased protease resistance. To determine how CECMP mutant AA substitutions affected HLA class I binding affinities of the peptides that contained the mutant AA, we first conducted a global assessment of HLA class I binding affinities for mutant peptides. Global analysis refers to the bulk use of a list of alleles that covers a large part of the population. Counts of high binding affinity peptides (ic50 < 50 nM) and intermediate binding affinity (50 nM < ic50 < 5000 nM) were obtained for the peptides representing increased and decreased sensitivity to the indicated proteases ( Table S12 .
Analyses of patient outcomes in terms of increased protease sensitivity of CECMPs
Patients with CECMP AA substitutions that lead to increased protease sensitivity (Methods) demonstrate longer overall survival and disease-free survival as compared to all remaining Normalization of number of epitopes representing an increase in protease sensitivity and an increase in resistance. Normalization was needed due to unequal number of input epitopes among the two different protease sensitivity alteration categories. These input sequences were obtained from the identified protease sensitivity alterations due to CECMP AA substitutions outlined above (Table  2) . Normalization was performed by multiplying the actual number of epitopes with increased protease resistance that bound HLA class I with the ratio of inputs of peptides with increased sensitivity to peptides with increased resistance.
patients (i.e., without CECMP AA substitutions or without AA substitutions that increased protease sensitivity) (Table 6 and Supporting Information, Tables S13 and S14). In particular, barcodes that represented CECMP AA substitutions with increased sensitivity to Neprilysin and Cathepsin S had significant overall survival increases, compared to barcodes without such CECMP AA substitutions (Figs. 4 and 5) . The median survival increase for barcodes representing patients with CECMP AA substitutions that lead to an increase in Neprilysin sensitivity was 87.84 months (versus all remaining barcodes) ( Table 6 ). The median survival increase for barcodes representing patients with CECMP AA substitutions that lead to an increase in Cathepsin S sensitivity was 34.1 months (vs barcodes without CECMP AA substitutions, in both cases) ( Table 6 ).
Discussion
CECMP coding regions are among the most commonly mutated coding regions in cancer, likely due to their large sizes and randomness of cancer mutagenesis. 20, 21 In the case of certain cancer types, including melanoma, mutations in these coding regions are driver mutation candidates. 22 While little is known about the impact of mutant AA in CECMPs, it is clear from noncancer settings that mutant polypeptides that contribute to polymers damage the formation of the polymers in a dominant negative fashion, as in osteogenesis imperfeta, 21 where mutant collagen subunits interfere with cartilage formation. Indeed, disorganized cytoskeletons can be a hallmark of tumorigenesis, 36 although this disruption may occur due to disrupted regulatory processes and has not yet been shown to be attributed to high-level CECMP mutations.
This report considers partially overlapping cancer phenomena that could, in part, explain the impact of CECMP mutant peptides on metastasis: increased protease sensitivity, in the case of cancer-associated proteases; and decreased availability for HLA class I binding, that is, decreased availability for stimulating an antitumor immune response. Cancer in general is often accompanied by high-level protease activity, due to either anomalous secretion of proteases by cancer cells or due to immune function cells, such as neutrophils, that have infiltrated the cancer microenvironment. The Table 6 with a median overall survival difference between protease sensitive barcodes versus all remaining barcodes, 34.1 months. This Kaplan-Meier (KM) analysis was generated with IBM statistical package for the social sciences (SPSS) software. Table 6 with a median overall survival difference between protease-sensitive barcodes vs all remaining barcodes, 87.84 months. This KM analysis was generated with IBM SPSS software.
protease activity is considered a possible explanation for local tissue breakdown and metastasis. Also, high level protease activity likely contributes to organ destruction and organ failure in the end stages of cancer. The above data indicate that patients with mutant peptides that confer increased protease sensitivity, for the protease's studied here, have a longer overall survival (Table 6 and Supporting Information, Tables S13 and S14); however, there is no explanation for such a distinction. Indeed, it is possible that the correlation with survival could be indirect, with a parameter such as mutation frequencies, or another parameter, being at the heart of the distinction. For example, more mutant peptides with increased protease sensitivity could represent more mutations overall and more genotoxicity.
Results above indicate that the vast majority of mutant peptides of the cytoskeleton-and ECM-related coding regions, in the case of melanoma, represent increase sensitivity for proteases known to be associated with melanoma. This study did not include a comprehensive set of possible AA variations, given the wild-type codon sequences and codon usage. Thus, this study cannot establish whether the increase in protease sensitive peptides is due to limitations on the alternative mutant amino acid possibilities or due to a selective pressure for protease sensitive amino acids. However, it is clear that, regardless of the fundamental or stochastic basis of the acquisition of mutant AA, in the case of melanoma, these mutant amino acids dramatically increase the protease sensitivity of CECMPs, based on the protease sensitivity algorithms employed. Thus, the above data are consistent with the conclusion that mutations in CECMP coding regions facilitate metastasis, particularly in the case of ECM-related coding regions. Interestingly, a recent report has described the anticancer effects of a protease resistant, ECM peptide. 37 It is also worth noting that preliminary studies with the TCGA-COAD and TCGA-BLCA datasets did not reveal any protease whereby the ratio of sensitive to resistant AA alterations was above 4, which is the lowest ratio represented by the melanoma-related, protease set applied to the TCGA-SKCM dataset above (Fig. 2a and Supporting Information, Table S6 ).
Interestingly, unlike HLA class II algorithms, HLA class I algorithms have developed to such an extent that their reliability in predicting epitope binding behavior is widely and routinely accepted and verifiable. The difference in the predictability of the two sets of algorithms is likely due to the flexibility of binding opportunities for the two sets of proteins, HLA class I and class II. For example, HLA class II binding clefts are open, allowing potential shifting alignments for epitope binding; and all HLA class II variants accommodate the monomorphic CLIP, 38 further indicating the unlikelihood of predicting HLA class II binding specificity on the basis of HLA class II allelic variations in the epitope binding cleft, coupled with the epitope AA sequence. The above data indicate that many of the mutant peptides that are relatively sensitive to the melanoma associated proteases also have high affinities for HLA class I. Furthermore, it has been demonstrated that protease sensitivity is a mechanism by which particular peptides can be either favored, or not, at least in the case of HLA class II binding. 21, 28 While this has not been demonstrated specifically for HLA class I binding, it would reasonable that potential HLA class I epitopes with a high affinity for a protease that is among the melanoma associated proteases, could be made available for binding to HLA class I. This hypothesis could be further substantiated with a more comprehensive cataloging of exactly where the mutant AA position is with respect to both the protease cut (hydrolysis) site and the HLA class I binding epitope near that cut site with the high affinity. For example, if the mutant AA is two AAs away from the cut site, as in Table 4 , and the best HLA class I binding epitope is represented by the peptide with the mutant AA two positions away from the end of the epitope, the relationship between protease sensitivity and HLA class I binding would be further substantiated. Regardless, it is quite striking that samples representing increased protease sensitivity, and thereby increased HLA class I binding affinities, also represent better survival rates, in some cases with relatively dramatic differences in median survival times (Table 6) . Furthermore, melanoma is among the most immunogenic of cancers, raising the question of whether a fortuitous combination of protease sensitive mutants, potentially facilitating breakdown of the ECM and metastasis, and simultaneously strong HLA class I binding mutants, explains that high level immunogenicity? As a related question, do cancers with less immunogenicity have means of metastasis that do not lead to freeing up peptides with high level HLA class I binding affinities?
